Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: New HIV diagnoses related to injection drug use (IDU) have declined in the United States. Access to clean syringes and decreasing HIV transmission among injection drug users have been HIV prevention priorities of the Rhode Island (RI) HIV community. To examine trends in IDU-related new HIV diagnoses in RI, we performed a retrospective analysis of new HIV diagnoses according to HIV risk factor from 1990-2003.
Results: There has been an 80% absolute reduction in IDU-related new HIV diagnoses in RI coincident with IDU-specific prevention efforts.
Conclusion: There has been a greater decline in IDU-related new HIV diagnoses in Rhode Island compared to national data reported by the Centers for Disease Control and Prevention. We hypothesize that this dramatic decline in Rhode Island is related to extensive HIV prevention efforts targeting IDUs. Further research is needed to examine the impact of specific HIV prevention interventions for injection drug users.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1698472 | PMC |
| http://dx.doi.org/10.1186/1747-597X-1-34 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diagnostic and Therapeutic Paradoxes in PCR-Positive, Histopathology-Negative CNS Aspergillosis in A Patient with HIV and Hodgkin Lymphoma.
Eur J Case Rep Intern Med
August 2025
Department of Internal Medicine, Wayne State University School of Medicine, Trinity Health Oakland Hospital, Pontiac, USA.
Background: Invasive central nervous system (CNS) aspergillosis is rare among human immunodeficiency virus (HIV)-positive patients due to preserved neutrophil function, despite significant CD4+ T-cell depletion. Diagnosis typically requires histopathologic confirmation, but polymerase chain reaction (PCR) testing has introduced new challenges due to its high sensitivity but limited specificity.
Case Presentation: We describe a newly diagnosed 43-year-old HIV-positive male with concurrent Hodgkin lymphoma who presented with progressive neurological decline and a ring-enhancing brain lesion.
Gut microbiota dysbiosis in people living with HIV who have cancer: novel insights and diagnostic potential.
Front Immunol
September 2025
Guangxi Key Laboratory of AIDS Prevention and Treatment & School of Public Health, Guangxi Medical University, Nanning, Guangxi, China.
Background: People living with HIV(PLWH) are a high-risk population for cancer. We conducted a pioneering study on the gut microbiota of PLWH with various types of cancer, revealing key microbiota.
Methods: We collected stool samples from 54 PLWH who have cancer (PLWH-C), including Kaposi's sarcoma (KS, n=7), lymphoma (L, n=22), lung cancer (LC, n=12), and colorectal cancer (CRC, n=13), 55 PLWH who do not have cancer (PLWH-NC), and 49 people living without HIV (Ctrl).
Protocol for a randomized controlled trial of patient-portal-based screening for substance use among people with HIV.
Front Public Health
September 2025
Department of Medicine, University of Chicago, Chicago, IL, United States.
Background: Achieving Equity in Patient Outcome Reporting for Timely Assessments of Life with HIV and Substance Use (ePORTAL HIV-S) is a research project funded by the National Institute for Drug Abuse to implement and evaluate multi-level interventions to decrease barriers to substance use screening and treatment for PLWH. At its center is a multidomain intervention addressing digital, sociocultural, and health care system environments, at individual, interpersonal, and community levels. ePORTAL HIV-S has four overall goals; this manuscript describes the protocol specifically for the randomized control trial (RCT) portion of the study.
View Article and Find Full Text PDFMulti-anatomical site prevalence of infection, resistance and association with coinfections: a prospective study in MSM with HIV.
JAC Antimicrob Resist
October 2025
Stanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong, Hong Kong, China.
Background: is a cause of sexually transmitted infections (STIs). This study assessed its prevalence, resistance and coinfection with / infections in MSM with HIV.
Methods: MSM in HIV care in Hong Kong were recruited during 2023-24 for completion of an online survey, and self-collection of urine specimens, rectal and pharyngeal swabs, which were tested for .
Clinical burden of HDV in Spain: Incidence, prevalence, and associated comorbidities.
JHEP Rep
October 2025
HEOR-Global Value and Access, Gilead Sciences, Inc., Foster City, CA, USA.
Background & Aims: HDV leads to the most severe form of viral hepatitis. It has been estimated to affect 5-13% of people who have chronic HBV worldwide. Evidence of HDV incidence, prevalence, and disease burden in Spain is limited.
View Article and Find Full Text PDF